Immunonutritional status, assessed by PNI and SII, significantly influences ovarian cancer prognosis, affecting survival outcomes and chemotherapy tolerance. High PNI and low SII correlate with longer ...

Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

BERLIN — The combination of pembrolizumab with weekly paclitaxel, with or without bevacizumab, leads to significant improvements in survival outcomes in patients with platinum-resistant recurrent ...

Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a large multicenter ...

Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from a phase 3 clinical trial of ...